Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants

L. van Oosten, J.J. Altenburg, Cyrielle Fougeroux, C. Geertsema, E.J. van den End, W.A.C. Evers, A.H. Westphal, S. Lindhoud, W.A.M. van den Berg, D.C. Swarts, L. Deurhof, Andreas Suhrbier, Thuy T. Le, S. Torres Morales, S.K. Myeni, Marjolein Kikkert, Adam F. Sander, Willem Adriaan de Jongh, Robert Dagil, Morten A. NielsenAli Salanti, Max Søgaard, T.M.P. Keijzer, D. Weijers, M.H.M. Eppink, R.H. Wijffels, M.M. van Oers, D.E. Martens, G.P. Pijlman*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants'. Together they form a unique fingerprint.

Medicine & Life Sciences